Table 10.

Novel therapies in clinical development in AML

Novel therapies in clinical development
Protein kinase inhibitors• FLT3 inhibitors (midostaurin, quizartinib, gilteritinib, crenolanib)
• KIT inhibitors
• PI3K/AKT/mTOR inhibitors
• Aurora and polo-like kinase inhibitors, CDK4/6 inhibitors, CHK1, WEE1, and MPS1 inhibitors
• SRC and HCK inhibitors
Epigenetic modulators• New DNA methyltransferase inhibitors (SGI-110)
• HDAC inhibitors
• IDH1 and IDH2 inhibitors
• DOT1L inhibitors
• BET-bromodomain inhibitors
Chemotherapeutic agents• CPX-351
• Vosaroxin
• Nucleoside analogs
Mitochondrial inhibitors• Bcl-2, Bcl-xL, and Mcl-1 inhibitors
• Caseinolytic protease inhibitors
Therapies targeting oncogenic proteins• Fusion transcripts targeting
• EVI1 targeting
• NPM1 targeting
• Hedgehog inhibitors
Antibodies and immunotherapies• Monoclonal antibodies against CD33, CD44, CD47, CD123, CLEC12A
• Immunoconjugates (eg, GO, SGN33A)
• BiTEs and DARTs
• CAR T cells or genetically engineered TCR T cells
• Immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4)
• Anti-KIR antibody
• Vaccines (eg, WT1)
Therapies targeting AML environment• CXCR4 and CXCL12 antagonists
• Antiangiogenic therapies
  • BiTE, bispecific T-cell engager; CAR, chimeric antigen receptor; DART, dual-affinity retargeting molecule; HDAC, histone deacetylase; KIR, killer-cell immunoglobulin-like receptor; mTOR, mechanistic target of rapamycin; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PI3K, phosphatidylinositol 3-kinase; TCR, T-cell receptor.